STOCK TITAN

Director John L. Lamattina receives LGND (LGND) RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026. He was granted 836 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 31,560 shares.

He was also granted a Non-Qualified Stock Option for 2,938 shares of common stock at an exercise price of 237.0000 per share, expiring on June 5, 2036. Both the RSUs and the option award fully vest on the earlier of the next annual meeting of company stockholders following the grant date or the first anniversary of the grant date.

Positive

  • None.

Negative

  • None.
Insider LAMATTINA JOHN L
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 2,938 $0.00 --
Grant/Award Common Stock 836 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 2,938 shares (Direct, null); Common Stock — 31,560 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
RSUs granted 836 shares Restricted stock units granted June 5, 2026
Options granted 2,938 options Non-Qualified Stock Option for common stock
Option exercise price 237.0000 per share Strike price for 2,938-share option grant
Option expiration June 5, 2036 Expiration date of granted Non-Qualified Stock Option
Shares held after RSU grant 31,560 shares Direct common stock holdings after RSU award
restricted stock units ("RSUs") financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with an exercise price of 237.0000 per share"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
annual meeting financial
"Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
vests financial
"Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAMATTINA JOHN L

(Last)(First)(Middle)
555 HERITAGE DRIVE
SUITE 200

(Street)
JUPITER FLORIDA 33458

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A836(1)A$0.031,560D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$23706/05/2026A2,938 (2)06/05/2036Common Stock2,938$0.02,938D
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
By: /s/ Andrew Reardon, Attorney-in-Fact For: John L. LaMattina06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did LGND director John L. Lamattina receive?

John L. Lamattina received 836 restricted stock units and a Non-Qualified Stock Option for 2,938 shares of Ligand common stock. These awards were granted by the board as part of director compensation at the June 5, 2026 annual meeting.

How do the new RSUs affect John L. Lamattina’s LGND share holdings?

The 836 RSUs increase John L. Lamattina’s direct common stock holdings to 31,560 shares after the grant. Each RSU represents a contingent right to receive one share of Ligand Pharmaceuticals common stock, subject to the stated vesting conditions.

What are the terms of John L. Lamattina’s new stock options in LGND?

He received a Non-Qualified Stock Option for 2,938 shares with an exercise price of 237.0000 per share, expiring on June 5, 2036. The options relate to Ligand common stock and vest based on the company’s director vesting schedule.

When do John L. Lamattina’s new LGND RSUs and options vest?

Both the 836 RSUs and the 2,938-share option grant fully vest on the earlier of the next annual meeting of Ligand stockholders following June 5, 2026, or the first anniversary of the June 5, 2026 grant date, aligning with the director compensation cycle.

Is John L. Lamattina’s Form 4 transaction a market purchase or sale of LGND stock?

The Form 4 reports compensation-related grants, not market trades. John L. Lamattina acquired RSUs and stock options from Ligand’s board at no cash price per share, rather than buying or selling shares in the open market.